2-(4-(2,4-dimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-methylbenzamide | 1448791-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-(2,4-dimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-methylbenzamide
• 英文别名: 2-[[4-(2,4-dimethoxyanilino)-1,3,5-triazin-2-yl]amino]-N-methylbenzamide
• CAS: 1448791-38-5
• 化学式: C₁₉H₂₀N₆O₃
• 分子量: 380.406
• InChiKey: WEFNPYOYKULUDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,4-二甲氧基苯胺 在 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 2-(4-(2,4-dimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-methylbenzamide
  参考文献：
  名称：

  Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity

  摘要：

  We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives as FAR (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells. Generally, the effects of these compounds on endothelial cells could be correlated with their kinase inhibitory activity. The most efficient compounds displayed inhibition of viability against HUVEC cells in the micromolar range, as observed with TAE-226, which was designed by Novartis Pharma AG. X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAR kinase domain is highly similar to that observed in the complex of TAE-226. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.038

文献信息

• Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity
  作者：Pascal Dao、Rafika Jarray、Johanne Le Coq、Daniel Lietha、Ali Loukaci、Yves Lepelletier、Réda Hadj-Slimane、Christiane Garbay、Françoise Raynaud、Huixiong Chen

  DOI：10.1016/j.bmcl.2013.06.038

  日期：2013.8

  We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives as FAR (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells. Generally, the effects of these compounds on endothelial cells could be correlated with their kinase inhibitory activity. The most efficient compounds displayed inhibition of viability against HUVEC cells in the micromolar range, as observed with TAE-226, which was designed by Novartis Pharma AG. X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAR kinase domain is highly similar to that observed in the complex of TAE-226. (C) 2013 Elsevier Ltd. All rights reserved.